Company SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
37.72 USD +3.46% Intraday chart for SpringWorks Therapeutics, Inc. -8.98% +3.34%

Business Summary

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Number of employees: 305

Sales per Business

USD in Million2022Weight2023Weight Delta
Life-changing Medicines
100.0 %
0 nan % 5 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 5 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 54 31/07/17
Chairman 65 31/12/15
Director of Finance/CFO 64 31/07/19
Chief Tech/Sci/R&D Officer 61 10/09/23
Chief Tech/Sci/R&D Officer 65 31/07/21
Chief Operating Officer 37 31/08/18
Investor Relations Contact - 31/07/18
Corporate Officer/Principal 58 21/03/21
Human Resources Officer 41 31/07/20
Comptroller/Controller/Auditor 53 31/10/19

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 31/07/19
Director/Board Member 69 31/07/17
Director/Board Member 61 13/07/22
Chairman 65 31/12/15
Chief Executive Officer 54 31/07/17
Director/Board Member 66 19/05/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,380,716 70,190,117 ( 94.37 %) 294,291 ( 0.3957 %) 94.37 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.94 %
11,068,026 14.94 % 417 M $
Vanguard Fiduciary Trust Co.
8.813 %
6,529,325 8.813 % 246 M $
BlackRock Advisors LLC
6.940 %
5,141,739 6.940 % 194 M $
T. Rowe Price International Ltd.
5.548 %
4,110,462 5.548 % 155 M $
Deep Track Capital LP
4.697 %
3,479,853 4.697 % 131 M $
Boxer Capital LLC
4.618 %
3,421,541 4.618 % 129 M $
Marshall Wace LLP
4.004 %
2,966,622 4.004 % 112 M $
2,961,624 3.998 % 112 M $
Lord, Abbett & Co. LLC
3.129 %
2,317,810 3.129 % 87 M $
Perceptive Advisors LLC
3.054 %
2,262,462 3.054 % 85 M $

Company contact information

Springworks Therapeutics, Inc.

100 Washington Boulevard

06902, Stamford

+

http://www.springworkstx.com
address SpringWorks Therapeutics, Inc.(SWTX)
  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. Company SpringWorks Therapeutics, Inc.